Krystal Biotech, Inc. (KRYS) stock

KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3042% above fair value

$305.23−0.45 (-0.15%)

Close on Nov 13, 2026Market cap $9.03BP/E 41.4Yield –

Krystal Biotech EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Krystal Biotech's EV/EBITDA was 41.9× on Nov 11, 2026, against 35.3× a year earlier. Over the last 2 years it ranged from 25.7× to 184.4×, with a median of 45.5×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	41.9×	+1.4
2025	Dec 31, 2025	40.5×	−101.4
2024	Dec 31, 2024	141.9×	–

Where these numbers come from

Parsed from the XBRL in Krystal Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing